Skip to content

Study · Randomized controlled trial · n = 31 · 2018

5 results

Adrenocorticotropic Hormone for Childhood Nephrotic Syndrome: The ATLANTIS Randomized Trial.

Wang CS, Travers C, McCracken C, Leong T, Gbadegesin R, Quiroga A, Benfield MR, Hidalgo G, Srivastava T, Lo M, Yadin O, Mathias R and 7 more

Show all authors

Araya CE, Khalid M, Orjuela A, Zaritsky J, Al-Akash S, Kamel M, Greenbaum LA

Clinical journal of the American Society of Nephrology : CJASN15 Nov 2018Cited by 11 (Europe PMC)

PMID30442868 (opens in a new tab)PMCIDPMC6302334 (opens in a new tab)DOI10.2215/cjn.06890618 (opens in a new tab)PepBankPUB-30442868
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In pediatric nephrotic syndrome, relapse occurred in 14/15 (93%) ACTH recipients versus 15/16 (94%) controls, without a significant difference (OR 0.93, 95% CI 0.05-16.40).

    In plain wordsIn pediatric nephrotic syndrome, repository corticotropin did not significantly reduce relapses versus no relapse-preventing treatment.

    Peptide
    ACTH (corticotropin)
    Outcome
    No significant changeRelapse within first 6 months
    Study

    n = 31

    Comparator
    No relapse-preventing treatment
    Analysis
    Primary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    80 U/1.73 m² twice weekly · 6 monthsAs given in this study (human).

    Measurements

    Participants with relapse in first 6 months
    93%
    ACTH arm, 14 of 15
    Participants with relapse in first 6 months
    94%
    control group, 15 of 16
    Relapse odds ratio
    0.93 ratio
    95% CI 0.05 to 16.40; P > 0.99

    Source sentences

    Summary
    Fourteen out of 15 (93%) participants in the ACTH arm experienced disease relapse in the first 6 months, with a median time to first relapse of 23 days (interquartile range, 9-32), compared with 15 out of 16 (94%) participants and at a median of 21 days (interquartile range, 14-51) in the control group.
    3 context sentences
    Summary · context
    There was no difference in the proportion of relapsed patients (odds ratio, 0.93; 95% confidence interval, 0.05 to 16.40; P>0.99) or time to first relapse (hazard ratio, 1.03; 95% confidence interval, 0.50 to 2.15; P=0.93).
    Summary · context
    Participants aged 2-20 years old with frequently relapsing or steroid-dependent nephrotic syndrome were enrolled from 16 sites in the United States and randomized 1:1 to ACTH (repository corticotropin injection) or no relapse-preventing treatment.
    Summary · context
    ACTH treatment regimen was 80 U/1.73 m2 administered twice weekly for 6 months, followed by 40 U/1.73 m2 administered twice weekly for 6 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In pediatric nephrotic syndrome, median time to relapse was 23 days with ACTH versus 21 days in controls, without a significant difference (HR 1.03).

    In plain wordsIn pediatric nephrotic syndrome, time to relapse did not differ significantly between repository corticotropin and no relapse-preventing treatment.

    Peptide
    ACTH (corticotropin)
    Outcome
    No significant changeTime to first relapse
    Study

    n = 31

    Comparator
    No relapse-preventing treatment
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    80 U/1.73 m² twice weekly · 6 monthsAs given in this study (human).

    Measurements

    Median time to first relapse
    23 days
    ACTH; interquartile range 9-32
    Median time to first relapse
    21 days
    Control; interquartile range 14-51
    Hazard ratio
    1.03 ratio
    95% CI 0.50 to 2.15; P = 0.93

    Source sentences

    Summary
    Fourteen out of 15 (93%) participants in the ACTH arm experienced disease relapse in the first 6 months, with a median time to first relapse of 23 days (interquartile range, 9-32), compared with 15 out of 16 (94%) participants and at a median of 21 days (interquartile range, 14-51) in the control group.
    3 context sentences
    Summary · context
    There was no difference in the proportion of relapsed patients (odds ratio, 0.93; 95% confidence interval, 0.05 to 16.40; P>0.99) or time to first relapse (hazard ratio, 1.03; 95% confidence interval, 0.50 to 2.15; P=0.93).
    Summary · context
    Participants aged 2-20 years old with frequently relapsing or steroid-dependent nephrotic syndrome were enrolled from 16 sites in the United States and randomized 1:1 to ACTH (repository corticotropin injection) or no relapse-preventing treatment.
    Summary · context
    ACTH treatment regimen was 80 U/1.73 m2 administered twice weekly for 6 months, followed by 40 U/1.73 m2 administered twice weekly for 6 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In pediatric nephrotic syndrome, no relapses occurred after ACTH dose reduction among the three participants who completed treatment.

    In plain wordsIn pediatric nephrotic syndrome, no relapses followed ACTH dose reduction among the three treatment completers.

    Peptide
    ACTH (corticotropin)
    Outcome
    Not applicableRelapse after dose reduction
    Study

    n = 3

    Analysis
    Secondary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    80 U/1.73 m² twice weekly for 6 months, then 40 U/1.73 m² twice weekly for 6 months · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no disease relapses after ACTH dose reduction among the three participants.
    2 context sentences
    Summary · context
    Participants aged 2-20 years old with frequently relapsing or steroid-dependent nephrotic syndrome were enrolled from 16 sites in the United States and randomized 1:1 to ACTH (repository corticotropin injection) or no relapse-preventing treatment.
    Summary · context
    ACTH treatment regimen was 80 U/1.73 m2 administered twice weekly for 6 months, followed by 40 U/1.73 m2 administered twice weekly for 6 months.
  4. 04HumanNon-randomized trialOther

    In pediatric nephrotic syndrome, 3 of 28 participants completed 12 months of repository corticotropin; others exited because of frequent relapses or side effects.

    In plain wordsIn pediatric nephrotic syndrome, 3 of 28 completed repository corticotropin treatment; others exited because of relapses or side effects.

    Peptide
    ACTH (corticotropin)
    Outcome
    Not applicableCompletion of ACTH treatment
    Study

    n = 28

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    80 U/1.73 m² twice weekly for 6 months, then 40 U/1.73 m² twice weekly for 6 months · 12 monthsAs given in this study (human).

    Measurements

    Participants completing 12 months of ACTH
    3 participants
    of 28 participants treated; others exited for frequent relapses or side effects

    Source sentences

    Summary
    Three out of 28 participants completed 12 months of ACTH treatment; the others exited the trial because of frequent relapses or side effects.
    2 context sentences
    Summary · context
    Participants aged 2-20 years old with frequently relapsing or steroid-dependent nephrotic syndrome were enrolled from 16 sites in the United States and randomized 1:1 to ACTH (repository corticotropin injection) or no relapse-preventing treatment.
    Summary · context
    ACTH treatment regimen was 80 U/1.73 m2 administered twice weekly for 6 months, followed by 40 U/1.73 m2 administered twice weekly for 6 months.
  5. 05HumanNon-randomized trialSafety outcome

    In pediatric nephrotic syndrome, most repository corticotropin side effects were mild and resembled corticosteroid side effects.

    In plain wordsIn pediatric nephrotic syndrome, most repository corticotropin side effects were mild and resembled corticosteroid side effects.

    Peptide
    ACTH (corticotropin)
    Outcome
    Not applicableSide effect severity
    Study

    n: not reported in source

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    80 U/1.73 m² twice weekly for 6 months, then 40 U/1.73 m² twice weekly for 6 months · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Most side effects were mild and similar to side effects of corticosteroids.
    2 context sentences
    Summary · context
    Participants aged 2-20 years old with frequently relapsing or steroid-dependent nephrotic syndrome were enrolled from 16 sites in the United States and randomized 1:1 to ACTH (repository corticotropin injection) or no relapse-preventing treatment.
    Summary · context
    ACTH treatment regimen was 80 U/1.73 m2 administered twice weekly for 6 months, followed by 40 U/1.73 m2 administered twice weekly for 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.